Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6P3S1

UPID:
DEN1B_HUMAN

ALTERNATIVE NAMES:
Connecdenn 2; Protein FAM31B

ALTERNATIVE UPACC:
Q6P3S1; B5MD89; D3PFD5; Q5T3B8; Q5T3B9; Q5T3C1; Q5TAI8; Q6B0I8; Q8NDT1; Q8TBE6; Q9H774; Q9NXU2

BACKGROUND:
The DENN domain-containing protein 1B, known alternatively as Connecdenn 2 or Protein FAM31B, is a key regulator of T-cell receptor (TCR) dynamics in TH2 cells. By acting as a Guanine nucleotide exchange factor for RAB35, it converts RAB35 to its active form, playing a vital role in clathrin-mediated endocytosis and cytokine production regulation.

THERAPEUTIC SIGNIFICANCE:
The dysregulation of DENN domain-containing protein 1B is linked to asthma, highlighting its significance in disease susceptibility. Its role in modulating TCR internalization and cytokine production in TH2 cells presents a promising avenue for developing targeted therapies for asthma, aiming to correct impaired TCR down-modulation and recycling.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.